openPR Logo
Press release

Endometriosis Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Organon, Ironwood Pharma, AbbVie, Neurocrine Biosciences, Mitsubishi Tanabe

02-25-2025 07:20 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Endometriosis Pipeline

Endometriosis Pipeline

"Endometriosis Pipeline Insight" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market.

The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Endometriosis Pipeline Report:
• Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years.
• Endometriosis companies working in the treatment market are Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment
• Emerging Endometriosis therapies in the different phases of clinical trials are- Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years.
• In October 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative treatments for advanced solid tumors and other serious diseases, has announced a sponsored research agreement with the University of Cincinnati. The agreement will explore the use of Lisata's novel cyclic peptide product, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for treating endometriosis. While bevacizumab has shown efficacy in treating endometriosis, its high dosage levels can cause systemic side effects, limiting its use in otherwise healthy young women. Lisata will provide funding and certepetide for the research conducted by the University of Cincinnati.

Get a Free Sample PDF Report to know more about Endometriosis Pipeline Therapeutic Assessment @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include:
• Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical
• MetriDx: Hera Biotech, Inc.
• BG2109: Bio Genuine (Shanghai) Biotech Co., Ltd.
• Relugolix Combination Tablet: Sumitomo Pharma Switzerland GmbH
• FOR 6219: Organon
• IW-3300: Ironwood Pharmaceuticals
• MT-2990: Mitsubishi Tanabe Pharma Corporation
• ORIAHNN (elagolix/estradiol/norethindrone acetate): AbbVie/Neurocrine Biosciences
• Linzagolix (OBE2109): ObsEva/Kissei Pharmaceuticals
• OVAREST (leuprorelin oral): SWK/Enteris BioPharma
• HMI-115: Bayer/Hope Medicine
• TU2670 (NCE-403): Tiumbio
• OG-6219: Organon
• Quinagolide: Ferring Pharmaceuticals
• Linzagolix: ObsEva

Endometriosis Route of Administration
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Endometriosis Molecule Type
Endometriosis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Endometriosis Pipeline Therapeutics Assessment
• Endometriosis Assessment by Product Type
• Endometriosis By Stage and Product Type
• Endometriosis Assessment by Route of Administration
• Endometriosis By Stage and Route of Administration
• Endometriosis Assessment by Molecule Type
• Endometriosis by Stage and Molecule Type

DelveInsight's Endometriosis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Endometriosis product details are provided in the report. Download the Endometriosis pipeline report to learn more about the emerging Endometriosis therapies @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key companies in the Endometriosis Therapeutics Market include:
Key companies developing therapies for Endometriosis are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.

Endometriosis Pipeline Analysis:
The Endometriosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
• Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Endometriosis drugs and therapies @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Endometriosis Pipeline Market Drivers
• The development of drug delivery systems represents a new approach in pain treatment among endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market.

Endometriosis Pipeline Market Barriers
• However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth.

Scope of Endometriosis Pipeline Drug Insight
• Coverage: Global
• Key Endometriosis Companies: Nanjing Chia-tai Tianqing Pharmaceutical, Hera Biotech, Inc., Bio Genuine (Shanghai) Biotech Co., Ltd., Sumitomo Pharma Switzerland GmbH, Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others
• Key Endometriosis Therapies: Elagolix, MetriDx, BG2109, Relugolix Combination Tablet, FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers

Request for Sample PDF Report for Endometriosis Pipeline Assessment and clinical trials @ https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Endometriosis Report Introduction
2. Endometriosis Executive Summary
3. Endometriosis Overview
4. Endometriosis- Analytical Perspective In-depth Commercial Assessment
5. Endometriosis Pipeline Therapeutics
6. Endometriosis Late Stage Products (Phase II/III)
7. Endometriosis Mid Stage Products (Phase II)
8. Endometriosis Early Stage Products (Phase I)
9. Endometriosis Preclinical Stage Products
10. Endometriosis Therapeutics Assessment
11. Endometriosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Endometriosis Key Companies
14. Endometriosis Key Products
15. Endometriosis Unmet Needs
16 . Endometriosis Market Drivers and Barriers
17. Endometriosis Future Perspectives and Conclusion
18. Endometriosis Analyst Views
19. Appendix
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Ventral hernia market- ttps://www.delveinsight.com/report-store/hernia-repair-devices-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Baricose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Pouchitis market- https://www.delveinsight.com/report-store/pouchitis-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Endometriosis Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Organon, Ironwood Pharma, AbbVie, Neurocrine Biosciences, Mitsubishi Tanabe here

News-ID: 3884624 • Views:

More Releases from DelveInsight Business Research LLP

Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical Stage Assets, Pharma Collaborations, Regulatory Developments, and the Global Market Growth Prospects
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Current Drug Trials, Potential Breakthrough Therapies, Pharma R&D Initiatives, and Future Market Transformations
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinical Advances, Pharma Strategies, and Market Evolution
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action, Ongoing Clinical Trials, Pharma Collaborations, and the Future Outlook of the Therapeutics Landscape
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights!

All 5 Releases


More Releases for Endometriosis

Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern. Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size? The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups. The
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five
Endometriosis Market Size, Share, Insight, Treatment 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Endometriosis Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $2.01 billion In 2028 At A
Endometriosis Market Trends, Size, Forecast - 2018-2023
Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases it may occur in other parts of the body. The endometriosis leads to various physical symptoms such as severe menstrual cramps, nausea and vomiting, fatigue, diarrhea, constipation, long-term pelvic pain, and